Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 108 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: abacavir (ABC)/lamivudine (3TC) Clear all
Completed Phase 4 Interventional

A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination

NCT00335270
View directory record Official record
Conditions
HIV
Interventions
fos-amprenavir calcium, ritonavir, abacavir/lamivudine as Epzicom
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2013 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 2 Interventional

A Study of a Combination of Four Drugs in Patients With Recent HIV Infection

NCT00002233
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Abacavir sulfate, Amprenavir, Lamivudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
15 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Not applicable Interventional

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

NCT00000919
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Hydroxyurea, Abacavir sulfate, Amprenavir, Nelfinavir mesylate, Efavirenz, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
63
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 1 Interventional

Study of GS-3242 in Participants With HIV-1; Substudy-05

NCT07001319
View directory record Official record
Conditions
HIV-1-infection
Interventions
GS-3242, BVY, Standard of Care
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Bakersfield, California • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 2, 2026, 3:22 PM EDT
Not listed Phase 3 Interventional

Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy

NCT00008554
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Nelfinavir mesylate, Lamivudine, GW433908
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
23
States / cities
Concord, California • Long Beach, California • Orlando, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 3 Interventional Results available

A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen

NCT02105987
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
ABC/DTG/3TC FDC, Ongoing cART regimen
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
87
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2017 · Synced Oct 2, 2026, 3:22 PM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1

NCT06630299
View directory record Official record
Conditions
HIV-1-Infection
Interventions
ISL/LEN, Antiretroviral Combinations
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 4 Interventional

A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients

NCT00005106
View directory record Official record
Conditions
HIV Infections
Interventions
Lamivudine/Zidovudine, Abacavir sulfate, Nelfinavir mesylate, Lamivudine, Stavudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
39
States / cities
Birmingham, Alabama • Tucson, Arizona • Longbeach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 3 Interventional Results available

Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects

NCT01449929
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
dolutegravir 50 mg OAD, darunavir 800mg OAD, ritonavir 100mg OAD
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed

NCT02603120
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
61
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 48 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects

NCT02539576
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
ABC/DTG/3TC FDC tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 3 Interventional

Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV

NCT00086359
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, lamivudine, and zidovudine, Lamivudine/zidovudine, Lopinavir/ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 4 Interventional Results available

A Simplification Study of Unboosted Reyataz With Epzicom (ASSURE)

NCT01102972
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
Reyataz + Norvir + Truvada, Reyataz + Epzicom
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
44
States / cities
Hobson City, Alabama • Phoenix, Arizona • Bakersfield, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

NCT00001119
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus Toxoid Vaccine, Indinavir sulfate, Lamivudine/Zidovudine, Ritonavir, Abacavir sulfate, Amprenavir, Efavirenz, Hepatitis B Vaccine (Recombinant), Lamivudine, Zidovudine
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 2, 2026, 3:22 PM EDT
Completed No phase listed Observational

Cellular Pharmacology and Platelet Effects of Abacavir and Lamivudine Anabolites

NCT04301661
View directory record Official record
Conditions
HIV-1-infection
Interventions
Blood collection, Abacavir/lamivudine, Tenofovir alafenamide/emtricitabine, Switch
Other · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT02607930
View directory record Official record
Conditions
HIV-1 Infection
Interventions
ABC/DTG/3TC, B/F/TAF, ABC/DTG/3TC Placebo, B/F/TAF Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
631 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
78
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 1 Interventional Results available

Study of Novel Antiretrovirals in Participants With HIV-1

NCT05585307
View directory record Official record
Conditions
HIV-1-infection
Interventions
Bavtavirine, B/F/TAF, Standard of Care (Substudy 01), GS-1720, Standard of Care (Substudy 02), GS-6212, Standard of Care (Substudy 03)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Long Beach, California • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 1 Interventional

Once-Daily Drug Regimen for HIV-Infected Patients

NCT00001968
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infections
Interventions
Amprenavir, Ritonavir, Abacavir, Lamivudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 4 Interventional

Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure

NCT00038506
View directory record Official record
Conditions
HIV Infection
Interventions
abacavir/lamivudine/zidovudine, tenofovir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
27
States / cities
Los Angeles, California • San Rafael, California • Fort Lauderdale, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2015 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 3 Interventional

A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

NCT00053638
View directory record Official record
Conditions
HIV Infection
Interventions
efavirenz, tenofovir, abacavir/lamivudine
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
58
States / cities
Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2010 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 1 Interventional

A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

NCT00002183
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Amprenavir, Lamivudine, Zidovudine
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
San Diego, California • Denver, Colorado • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 3 Interventional

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

NCT00013520
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate, Lamivudine and Zidovudine, Atazanavir, Lamivudine/Zidovudine, Abacavir sulfate, Efavirenz, Nevirapine, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
59
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents

NCT00915655
View directory record Official record
Conditions
HIV-1 Infection
Interventions
darunavir, ritonavir, zidovudine, lamivudine, abacavir
Drug
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Industry
Eligibility
12 Years to 18 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 2, 2026, 3:22 PM EDT
Completed Phase 3 Interventional Results available

A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT

NCT00727597
View directory record Official record
Conditions
Human Immunodeficiency Virus Infections
Interventions
Efavirenz 600mg, Boosted Lexiva
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2013 · Synced Oct 2, 2026, 3:22 PM EDT